Atriopeptin (AP) is stored as the prohormone AP-126 [atrial natriuretic factor-(1-126)] in atrial granules.
The prohormone form of secreted proteins (e.g., proinsulin, preopiomelanocortin, and proenkephalin) are proteolytically cleaved to the mature hormone during vesicular packaging (1) (2) (3) . Subsequent stimulation-secretion-coupling results in the release ofmature hormone during exocytosis. In contrast, the prohormone atriopeptin (AP)-126 [atrial natriuretic factor (ANF)- ] is stored in the atrial granules as the unprocessed prohormone (4) . Cultured fetal or neonatal atrial myocytes release intact prohormone into the incubation medium in both the basal state (5) and when stimulated by stretch with hypotonic medium (6) . On the other hand, isolated perfused rat or rabbit hearts only release mature hormone, AP-28 [ANF-(99-126)] (7) (8) (9) . After treatments that stimulate AP secretion by atrial stretch such as volume expansion, vasoconstrictors, and water immersion, the circulating plasma forms of AP are AP-28 and the N-terminal fragment, AP-(1-98) (10, 11) . Only in cases of severe cardiomyopathy have plasma levels of intact prohormone been detected in vivo (12) (13) (14) . Thus, under normal circumstances, AP is stored as the prohormone in granules and, under conditions of atrial stretch, release and processing are virtually simultaneous events. The tissue site and mechanism of the selective cleavage of AP-126 between Arg-98 and Ser-99 is unresolved. Enzymes have been isolated from atrial tissue that describe the selective cleavage of prohormone (15, 16) , but the cardiac cellular and subcellular localization of these enzymes has not been resolved. The inability of the cultured atrial myocyte to cleave the prohormone either suggests that the cell source is not necessarily the processing site or that the isolation or culturing conditions inactivate the cleavage enzyme.
In the present study, we studied AP prohormone processing in the isolated, perfused rat heart, thereby precluding (i) the necessity to use enzymes (which could alter processing) in the isolation of cell types as in tissue culture experiments and (ii) the noncardiac processing that might occur in vivo in plasma or other tissues.
MATERIALS AND METHODS
Materials. AP-126-Arg-Arg (11), representing amino acid residues 25-152 of the rat preprohormone coding sequence (17) , was produced in Escherichia coli by using recombinant DNA techniques. The amino acid sequence was confirmed by gas-phase sequence analysis. AP-126-Arg-Arg was chosen as an exogenous prohormone substrate for the proteolytic processing experiments because it contained the complete amino acid sequence for the cleavage site between Arg-98 and Ser-99. This substrate also contains the two C-terminal arginine residues coded by the genomic cDNA that are absent from the atrial storage.
Isolated Perfused Heart. Male Sprague-Dawley rats weighing between 225 and 275 g were anesthetized with chloral hydrate (350 mg/kg, i.p.) and anticoagulated with heparin (100 units i.v.). The hearts were excised and immediately placed in ice-cold Krebs-Henseleit buffer. The aorta was cannulated, and the hearts were perfused at 10 ml/min with oxygenated Krebs-Henseleit solution (37°C; 5% C02/95% 02) and were allowed to equilibrate for 30 min. The composition of the Krebs-Henseleit solution was 120 mM NaCI/4.7 mM KCI/1.2 mM MgSO4/2.5 mM CaCl2/1.2 mM KH2PO4/25 mM NaHCO3/10 mM dextrose. The composition of the calcium-deficient medium was 120 mM NaCl/4.7 mM KCI/1.2 mM MgSO4/1.2 mM KH2PO4/25 mM NaHCO3/10 mM dextrose/i mM EGTA. Samples from consecutive 10-min cardiac effluent collections were collected and stored at -70°C until assayed by AP enzyme immunoassay as previously described (18) . Cardiac effluent (100 ml) was concentrated on a C18 Sep-Pak column (Baker) and was washed with 10 ml of water; the absorbed peptide was eluted with a solution of 80% methanol in 0.1% trifluoroacetic acid. After lyophilization, the residue was dissolved in water containing 0.05% trifluoroacetic acid for further HPLC analysis.
Abbreviations: AP, atriopeptin; ANF, atrial natriuretic factor; APir, AP immunoreactivity; NTFir, N-terminal fragment immunoreactivity.
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The publication costs of this article were defrayed in part by page charge payment. This article must therefore be hereby marked "advertisement" in accordance with 18 U.S.C. §1734 solely to indicate this fact. HPLC Analysis. A rapid (i.e., <15 min) qualitative HPLC separation could be achieved on a precolumn column (RP-300, Vydac) with a trifluoroacetic acid/acetonitrile solvent system at a flow rate of 2.0 ml/min (solvent A, 0.05% trifluoroacetic acid in water; solvent B, 0.05% trifluoroacetic acid in acetonitrile). The samples were resolved by stepwise elution with solvent B as follows: at 1 min, 25%; and at 10 min, 80%. Aliquots of each fraction were Iyophilized and analyzed by AP enzyme immunoassay. The retention time of standards were as follows: AP-28 and AP-24, 5 min; and AP-126, 13 min.
The analytical HPLC separation was carried out on a Vydac C18 reverse-phase column at a flow rate of 1.0 ml/min with a trifluoracetic acid/acetonitrile solvent system (solvent A, 0.05% trifluoroacetic acid in water; solvent B, 0.05% trifluoroacetic acid in 80% acetonitrile). The following linear gradients in B were applied: at 5 min, 0-23%, duration 20 rA Atrial Extracts portions of the C terminus of the prohormone [AP-(1-126), i.e., ANF-(1-126)] that contain the natriuretic' diuretic sequence AP-(99-126) (i.e.,' AP-28), and the data obtained with this antibody were described as AP immunoreactivity (APir) (19) . The second antibody recognizes the N-terminal fragment of the prohormone but does not cross-react with the C-terminal AP-28 (11) . Both antibodies can detect the intact prohormone.
Rat atrial extracts were prepared by boiling frozen homogenates from numerous animal's in 1.0 M acetic acid (17) and were subjected to immunoassay with both antisera. There was a direct linear relationship, in a 1:1 ratio, between APir and N-terminal fragment immunoreactivity (NTFir) (Fig.  LA) , which is consistent with the existence of only a single peak of prohormone on HPLC analysis of the atrial extracts (data not shown).
In vivo there is a 4-10 times higher level of NTFir than APir in plasma following stimulation of AP release (11) . This differential in' plasma levels of the cleavage products of AP-126 arises from differential in vivo half-life observed for each fragment [i.e., -30 sec for AP-28 and 300 sec for AP-(1-98) (11)]. However, the AP fragments present in the coronary venous effluent are independent of'plasma or tissue degradation systems and were found to be present in the predicted 1:1 ratio of APir to NTFir (Fig. 1B) . HPLC analysis of the coronary venous effluent of medium-perfused rat and rabbit hearts indicated the presence of mature hormone AP-28 and little or no prohormone (7) (8) (9) .
Stretch-Induced AP Release. Atrial pressure was varied by manipulation of atrial afterload by means of adjustment of the cannula leading into the right atrium. A direct linear relationship between increasing afterload (up to 40 mmHg) and right atrial pressure (up to 48 mmHg) was observed. However, APir released was only linear between 0 and 10 mmHg of right atrial pressure; thus, the stretch experiments were performed at 10 m'mHg. These data are in good agreement with the previous report in which rat atrial pressure was increased between 0.4 and 4.5 mmHg'and exhibited a linear correlation between the APir release and the change in atrial pressure (20) . Twenty minutes of continuous stretch resulted in a profound increase in APir detectable in the coronary venous effluent of the perfused rat heart (Fig. 2A) . Cessation of stretch resulted in the rapid recovery to basal APir levels. The amount of APir released by the perfused hearts decreased if the stretch was continued for longer time periods.
-.5r Intracellular calcium has been suggested to be a modulator of hormone secretion. We therefore tested the response of isolated rat hearts that were perfused in calcium-deficient medium in the presence of 1 mM EGTA. Switching the perfusion medium from normal Krebs to calcium-deficient Krebs abolished the spontaneous cardiac contractility without changing the basal peptide release of AP. The detectable total APir released by stretch was partially suppressed in the calcium-depleted hearts (Fig. 2B) .
One hundred milliliter aliquots (i.e., 10 min of perfusion at a medium flow of 10 ml/min) of the coronary venous effluent was pooled, -concentrated on a C18 reverse-phase column, eluted, lyophilized, reconstituted in the mobile solvent phase, and separated on the reverse-phase HPLC column to elucidate the molecular form of AP present in the effluent. As anticipated, stretch caused the release of the low molecular weight C-terminal peptide (which comigrates with the AP-28 standard) and little or no detectable prohormone (Fig, 3A) . Surprisingly, rat hearts perfused with calcium-deficient Krebs medium containing EGTA released primarily prohormone when stretched (Fig. 3B) .
Neither the mechanism nor the cardiac site by which the lack of Ca2 + interferes with prohormone processing is resolved by these experiments. Since aprotinin (Trasylol) has previously been demonstrated to block AP prohormone processing by cardiac tissue, we studied the influence of this enzyme inhibitor in the isolated perfused rat heart. The aprotinin perfusion (5 units/ml, final concentration) preceded and was continued for the first 10 min of stretch, and the remaining 20 min of stretch was performed in the absence of enzyme inhibitor. The release of total APir was highest in the first 10 min of stretch (period A) and diminished with time (period B) (Fig. 4 Upper). HPLC analysis of the pooled coronary venous effluent clearly indicated that the aprotinin suppressed prohormone processing (Fig. 4 Lower, trace A) . The ratio of prohormone to mature hormone was 1.7 when stretch was performed in the presence of aprotinin (Fig. 4 Lower, trace A), fell to 0.7 upon withdrawal of the enzyme inhibitor (Fig. 4 Lower, trace B), and recovered to the basal ratio of 0.3 during the remaining 10 min.
Processing of Exogenous Prohormone. The ability of aprotinin to suppress the conversion of endogenous prohormone suggests that processing could be occurring in the extracellular space. We therefore, studied the conversion of exogenous prohormone by the perfused rat heart. Recombinant prohormone AP-126-Arg-Arg was utilized as a source of exogenous prohormone. Recirculation experiments were performed in a small total volume of medium because only a limited supply of prohormone was available. The perfusion medium was oxygenated in a reservoir distal to the heart, and a filter was in line to remove any particulate matter. The perfusion apparatus was precoated with silicone, and recirculation of prohormone in the absence of a rat heart did not result in the loss of peptide by adherence to the foreign surfaces (control in Fig. 5 ). Exogenous prohormone was added to the perfusion medium and was recirculated through the heart. Aliquots of the medium were collected for direct assay of total APir, and the remainder was concentrated and assayed by a short column HPLC to qualitatively identify the molecular form of AP. The isolated heart exhibited a linear conversion of the high molecular weight prohormone into the low molecular weight C-terminal AP (Fig. 5) , which on analytical HPLC comigrated with AP-28-Arg-Arg and was ATRIAL MYOCYTE Stretch confirmed by amino acid sequence analysis. Inclusion of the aprotinin in the recirculating medium containing the exogenous prohormone blocked the degradation of the AP-126-Arg-Arg (Fig. 5) .
DISCUSSION
In the present investigation, we have demonstrated that prohormone processing in the isolated rat heart could be suppressed either by depletion of calcium or with the proteolytic enzyme inhibitor aprotinin. Since exogenous aprotinin would be restricted to the extracellular space, blockade of processing suggests that endogenous prohormone is released intact from the atrial myocyte. This possibility is supported by the demonstration that exogenous prohormone processing is also blocked by aprotinin. The release of AP-126 from intact hearts is consistent with the release of prohormone by cultured atrial myocytes (5) . We earlier demonstrated that urinary or submaxillary kallikrein mimicked the cardiac cleavage processes since the pure enzymes catalyzed the conversion of prohormone to mature hormone and that this proteolytic activation was blocked by aprotinin but not by soybean trypsin inhibitor (21) .
The precise location of the processing enzyme remains unclear. Ifthe enzyme is present in the storage granule, either it would have to exist in an inactive form that is instantly fully activated at the time of stimulated release, or alternatively the enzyme is on the exterior of the granule or on the atrial myocyte surface at the site of granule fusion. Stretch has been demonstrated to cause fusion of the atrial granule membrane with the monocyte membrane, presumably at the time of AP release (22) . Recently, an enzyme that selectively cleaves AP prohormone has been isolated from bovine atrial granules (16) . The inability of aprotinin to completely block prohormone processing induced by stretch (Fig. 4 Lower) suggests the possibility of some granular-dependent proteolysis as well as in the extracellular compartment.
An alternative hypothesis, which we favor, is that AP-126 is released by the atrial myocyte during stretch into the extracellular space and is processed by the adjacent mesenchymal cells. Cultured neonatal atrial mesenchymal cells readily process exogenous prohormone to the low molecular weight C-terminal AP peptide (J. Greenwald and P.N., unpublished data). The cardiac mesenchymal cells were previously shown to contain specific cell surface AP receptors (23) . In animals or humans with severe cardiomyopathy, circulating levels of AP prohormone have been found (12) (13) (14) 24 prohormone to a secondary processing cell, which most ideally should be in intimate contact with the atrial myocyte.
The mechanism by which calcium-deficient medium interferes with prohormone processing is unknown. One possibility is that the cleavage enzyme is calcium dependent. Another possibility is that, in the absence of calcium, cellular contact between atrial myocytes and mesenchymal cells is disturbed, thereby precluding instantaneous processing. HPLC analysis of the total APir released by stretch indicates that in calcium-depleted medium the total APir release has been doubled (Fig. 3 A and B) ; furthermore, AP-126 is only 50% cross-reactive with AP-28 with this antibody employed in the immunoassay. We observed that hypotonic stretch of cultured atrial myocytes induced the release of APir, which was enhanced (10-to 13-fold) when the cells were incubated in calcium-depleted medium containing EGTA or when the cells were pretreated with the intracellular calcium antagonist, 1, 2-bis(2-aminophenoxy)ethane N,N,N',N'-tetraacetic acid (6) .
A hypothetical model for the concerted release and processing of AP prohormone, released by right atrial stretch, as a two-cell process is presented in Fig. 6 . Multiple sites of proteolytic cleavage might exist, possibly accommodating AP prohormone constitutively released from within the cell or AP prohormone regulatively released through exocytosis involving direct granular fusion with the cell membrane and extrusion of its contents. Resolution of the localization of the specific cleavage enzyme requires additional experimentation. Recently, AP cleavage enzymes have been purified (15, 16) . If specific antibodies can be developed, careful immunocytochemistry could decisively localize the compartmentation of the enzyme. The prohormone is considerably less active than the processed mature hormone (25) . The cleavage enzyme "activates" the peptide; thus, pharmacological processing would be expected to allow manipulation of the AP hormonal system.
